True DisCoVeRy of COVID-19 Disease Burden Versus Speculated Antiviral Cardiovascular Risk Requires a Control Group

Clin Infect Dis. 2024 Aug 16;79(2):392-394. doi: 10.1093/cid/ciae172.

Robert L Gottlieb^{1

2

3

4}, Andre C Kalil⁵

¹ Department of Internal Medicine, Baylor University Medical Center, Baylor Scott & White Health, Dallas, Texas, USA.
² Baylor Scott & White Research Institute, Dallas, Texas, USA.
³ Department of Internal Medicine, Burnett School of Medicine at Texas Christian University (TCU), Fort Worth, Texas, USA.
⁴ Department of Internal Medicine, Texas A&M Health Science Center, Dallas, Texas, USA.
⁵ Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

No abstract available

Keywords: Covid-19; adverse events; control; remdesivir; safety.

Publication types